HomeCompareLSIIF vs ABBV

LSIIF vs ABBV: Dividend Comparison 2026

LSIIF yields 0.77% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.6K in total portfolio value
10 years
LSIIF
LSIIF
● Live price
0.77%
Share price
$59.03
Annual div
$0.46
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.8K
Annual income
$81.48
Full LSIIF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LSIIF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLSIIFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LSIIF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LSIIF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LSIIF
Annual income on $10K today (after 15% tax)
$65.86/yr
After 10yr DRIP, annual income (after tax)
$69.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,986.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LSIIF + ABBV for your $10,000?

LSIIF: 50%ABBV: 50%
100% ABBV50/50100% LSIIF
Portfolio after 10yr
$61.6K
Annual income
$12,426.62/yr
Blended yield
20.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LSIIF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
3.6
Piotroski
9/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LSIIF buys
0
ABBV buys
0
No recent congressional trades found for LSIIF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLSIIFABBV
Forward yield0.77%3.06%
Annual dividend / share$0.46$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$20.8K$102.3K
Annual income after 10y$81.48$24,771.77
Total dividends collected$796.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: LSIIF vs ABBV ($10,000, DRIP)

YearLSIIF PortfolioLSIIF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,777$77.48$11,550$430.00$773.00ABBV
2$11,610$78.04$13,472$627.96$1.9KABBV
3$12,501$78.57$15,906$926.08$3.4KABBV
4$13,455$79.07$19,071$1,382.55$5.6KABBV
5$14,477$79.53$23,302$2,095.81$8.8KABBV
6$15,570$79.97$29,150$3,237.93$13.6KABBV
7$16,740$80.39$37,536$5,121.41$20.8KABBV
8$17,993$80.77$50,079$8,338.38$32.1KABBV
9$19,334$81.14$69,753$14,065.80$50.4KABBV
10$20,769$81.48$102,337$24,771.77$81.6KABBV

LSIIF vs ABBV: Complete Analysis 2026

LSIIFStock

Lisi S.A. provides assembly and component solutions for the aerospace, automotive, and medical industries in France and internationally. It operates through three divisions: LISI Aerospace, LISI Automotive, and LISI Medical. It offers titanium nuts, lightning strike protection, safety locks, and fuse pins; compressor blade and strut for the LEAP engine; LEAP engines composite fan blade leading edge; air intake lipskin for the airbus; power transmission semi-machined gears; stator vanes; and satellite antenna brackets for airplanes and helicopters. It also provides guide pins and electric parking brakes; braking systems and direct engine injections; screws and nuts; belt and seat mechanism products; special parts for motors and safety systems; clips for interior and exterior trim; assembly reduction and optimization solutions; and cable ducts. In addition, it offers assembly solutions, battery fastening systems, complex power transmission parts, and other automotive standard fasteners; clipped fastening systems for interior and exterior cladding, fasteners for tubes and cables, as well as solutions for weight reduction and optimizing assemblies; and covers components for braking, fluid management, and seat adjustment and interior safety systems. Further, it engages in the designing and modeling, prototypes, pre-series, materials, process validation, and replenishment of inventories; offers shoulders, reconstruction implants solutions for hips, knees, extremities, and instruments; blades, scissors, staplers, and pliers for surgery; and spinal and trauma implants, such as connectors, screws, cages, plates, and prostheses medical devices for treating trauma and osteosynthesis. The company was formerly known as GFI Industries and changed its name to LISI S.A. in 2002. The company was founded in 1777 and is headquartered in Belfort, France. Lisi S.A. operates as a subsidiary of Compagnie Industrielle De Delle S.A.

Full LSIIF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LSIIF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LSIIF vs SCHDLSIIF vs JEPILSIIF vs OLSIIF vs KOLSIIF vs MAINLSIIF vs JNJLSIIF vs MRKLSIIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.